Abstract
The first experimental immunization of humans against the AIDS retrovirus, HIV-1, was started in a series of HIV seronegative, healthy volunteers in November 19861. For the primary vaccination recombinant vaccinia virus (V25)2 expressing the complete gp160 env protein3 of the HTLV-IIIB strain4,5 of HIV-1 was introduced by scarification. This elicited a weak primary response which we subseqently attempted to enhance by additional immunizations (boosting), using four different immunization protocols. We report here that intravenous injection of paraformaldehyde-fixed autologous cells infected in vitro with V25 (individual D.Z.) gave the best results. This individual received second and third boosts of intramuscular gp160 derived from an HTLV-IIIB clone using the hybrid vaccinia virus/bacteriophage T7 expression system6. An anamnestic humoral and cellular immune reaction was achieved for over one year after the original vaccination, with high levels of antibodies to the viral envelope, and neutralizing antibodies against divergent HIV-1 strains such as HTLV-IIIB4,5,7 and HTLV-IIIRF (also called HTLV-III HAT)3,5 after the first boost. In addition, group-specific cell-mediated immunity and cell-mediated cytotoxicity against infected T4 cells were obtained after the primary vaccine and enhanced by the boosts. Finally, skin tests showed both immediate and delayed hypersensitivity to gp160 in vivo. Although this protocol is not practical for a large scale vaccine trial, our results show for the first time that an immune state against HIV can be obtained in man.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zagury, D. et al. Nature 326, 249–250 (1987).
Chakrabarti, S. et al. Nature 320, 535–537 (1986).
Hahn, B. H. et al. Proc. natn. Acad. Sci. U.S.A. 87, 4813–4817 (1985).
Popovic, M. et al. Science 224, 497–500 (1984).
Wong-Staal, F. & Gallo, R. C. Nature 317, 395–403 (1985).
Fuerst, T. R., Earl, P. L. & Moss, B. Molec. cell Biol. 7, 2538–2544 (1987).
Gallo, R. C. et al. Science 224, 500–503 (1984).
Zagury, D. et al. Science 231, 850–853 (1985).
Leonard, R. et al. Proc. natn. Acad. Sci. U.S.A. (in the press).
Starcich, B. R. et al. Cell 45, 637–648 (1986).
Robert-Guroff, M. et al. Nature 316, 72–74 (1986).
Wong-Staal, F. et al. Science 229, 759–762 (1985).
Cease, K. et al. Proc. natn. Acad. Sci. U.S.A. 84, 4249–4253 (1987).
Acharya, A. L. et al. N. Engl. J. Med. 317, 1101–1109 (1987).
Nara, P. L. et al. AIDS Res. hum. Retroviruses (in the press).
Salahuddin, S. Z. et al. Proc. natn. Acad. Sci. U.S.A. 82, 5530–5534 (1985).
Zarling, J. et al. Nature 323, 344–346 (1986).
Franchini, G. et al. AIDS Res. hum. Retroviruses 3, 11–17 (1987).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zagury, D., Bernard, J., Cheynier, R. et al. A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature 332, 728–731 (1988). https://doi.org/10.1038/332728a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/332728a0
This article is cited by
-
The Antibodiome—Mapping the Humoral Immune Response to HIV
Current HIV/AIDS Reports (2019)
-
Membrane-anchored CCL20 augments HIV Env-specific mucosal immune responses
Virology Journal (2017)
-
The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible?
Nature Reviews Immunology (2002)
-
A naturally unbalanced combat
Nature Medicine (1997)
-
Papillomavirus Vaccines
Clinical Immunotherapeutics (1994)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.
